| Prev Close | 24.75 |
| Open | 24.67 |
| Day Low/High | 24.28 / 24.76 |
| 52 Wk Low/High | 28.82 / 46.24 |
| Volume | 641.38K |
| Avg Volume | 1.06M |
| Exchange | NASDAQ |
| Shares Outstanding | 68.12M |
| Market Cap | 1.68B |
| EPS | 1.80 |
| P/E Ratio | 54.93 |
| Div & Yield | N.A. (N.A) |
Latest News
Crescendo Bioscience Announces Six Studies With Vectra® DA Will Be Presented At The 2017 Annual European Congress Of Rheumatology
Clinical Utility of Vectra® DA Further Demonstrated with New Data on Prediction of Joint Damage
Noteworthy Monday Option Activity: MYGN, MXWL, GIII
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Myriad Genetics, Inc. , where a total of 5,567 contracts have traded so far, representing approximately 556,700 underlying shares.
Myriad's BRACAnalysis CDx® Test Identified Patients With Metastatic Breast Cancer Who Benefited From Treatment With Olaparib In Phase 3 OlympiAD Study
Company to Seek FDA Approval of BRACAnalysis CDx Test in HER2- Metastatic Breast Cancer
Myriad Announces 17 Additional Health Insurance Plans Covering EndoPredict™
Coverage Decisions Add 35 Million Additional Covered Lives Bringing Total to 109 Million
Myriad Genetics Announces Results From A Large 2,000 Patient Clinical Utility Study Of Its MyRisk® Hereditary Cancer Test At The 53rd Annual Meeting Of ASCO
50 Percent of Mutations Were Found in Patients Who Do Not Meet Current Testing Guidelines; 34 Percent of Mutations Were Identified In Unexpected Genes
Medicare Coverage Of Prolaris® Test Expands With The Addition Of Men Diagnosed With Favorable Intermediate Risk Prostate Cancer
Prolaris Now Accessible to 70 percent of Medicare Patients with Prostate Cancer
Myriad Genetics To Present Seven Studies At The 2017 American Society of Clinical Oncology Annual Meeting
Presentations Highlight Continued Advancements in Hereditary Cancer Panel Testing
Myriad Genetics' Prolaris® Test Accurately Predicts The 10-Year Risk Of Metastases In Men Treated For Prostate Cancer
Strong Predictive Power in Both African American and Non-African American Patients
Myriad Genetics To Present Results From Four Studies At The American Urological Association 2017 Annual Meeting
Featured Study Will Show Power of the Prolaris Test to Predict 10-Year Risk of Metastases in Men Treated for Prostate Cancer
Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma
Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.
Study Finds Wide Gap In Quality Of BRCA1/2 Variant Classification Between Myriad Genetics And A Common Public Database
26 Percent Discordance Rates Observed in Public Databases
Myriad Genetics And BeiGene Sign Agreement To Develop Companion Diagnostics For Use With BeiGene's Novel PARP Inhibitor, BGB-290
Collaboration Will Evaluate Myriad's myChoice® HRD and BRACAnalysis CDx® Tests
Pivotal Study Results For Myriad's MyPath® Melanoma Test Highlighted In Two Additional Scientific Publications
The Company Will Seek Reimbursement from Medicare and Private Payers
Myriad Genetics Announces Five Scientific Presentations At The 2017 American College Of Medical Genetics Annual Clinical Genetics Meeting
New Data Will Highlight Advances in Genetic Variant Classification for Hereditary Cancers
Myriad Genetics Launches The EndoPredict® Test In The United States For Patients With Breast Cancer
Second-Generation Test Provides More Accurate 10-Year Recurrence Risk for Patients Diagnosed with ER+ HER2- Early-Stage Breast Cancer
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABCO, AEGN, AVGO, GKOS, GPT, GTN, MYGN, SINO, THRM Downgrades: AN, CODI, PRGX, TAIT, TREC Initiations: BMCH Read on to get TheStreet Quant Ratings' detailed report:
GeneSight® Psychotropic Test Demonstrated Substantial Cost Savings For Payers In New Study Published In Clinical Therapeutics
Economic Utility Study Showed Annual Cost Savings of $3,988 per Member
Myriad's Prolaris® Test Significantly Improves The Risk Classification For One Third Of Men Diagnosed With Localized Prostate Cancer
New Data from 16,000 Patient Study to Be Presented at 2017 ASCO GU
Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics
Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.
Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments
Cramer points to Gilead's pipeline for its problems.
